Document is current
Any future updates will be listed below
-
Authors
Bagley, Sarah M. https://orcid.org/0000-0002-7524-0178
Chavez, Laura
Braciszewski, Jordan M.
Akolsile, Mary
Boudreau, Denise M.
Lapham, Gwen
Campbell, Cynthia I.
Bart, Gavin
Yarborough, Bobbi Jo H.
Samet, Jeffrey H.
Saxon, Andrew J.
Rossom, Rebecca C.
Binswanger, Ingrid A.
Murphy, Mark T.
Glass, Joseph E.
Bradley, Katharine A.
,
Szapocznik, José
Liebschutz, Jane M.
Ahmedani, Brian K.
Pflugeisen, Bethann Mangel
Schwartz, Robert P.
Stotts, Angela L.
Northrup, Thomas F.
Horigian, Viviana E.
Silva, Angela J.
-
Funding
Funding for this research was provided by:
National Institute on Drug Abuse (UG1DA040314, K23DA044324, 5 UG1 DA013714-18, UG1DA013720, UG1DA040316, 5 UG1 DA049436-03, U10 DA013714)
National Institute on Alcohol Abuse and Alcoholism (K01AA023859)
- License Information
-
More Information
Article History
Received: 7 January 2021
Accepted: 9 June 2021
First Online: 7 July 2021
Declarations
:
: The study was approved by the Kaiser Permanente Washington Institutional Review Board (IRB), and other sites ceded to the Kaiser Permanente Washington IRB.
: Not applicable.
: Dr. Yarborough has received support through her institution from Syneos Health to conduct FDA-mandated post-marketing research on the risks of opioid analgesic use. Dr. Schwartz has served as a consultant to Verily Life Sciences.
